lunedì, 4 maggio 2026

Notizie Newsletter

NCI Designations Propel Innovation at Two Prestigious Cancer Institutions

Aug 17, 2019 - Residents of Indiana now have a National Cancer Institute (NCI)-designated Comprehensive Cancer Center in their state, and Floridians have another designated Cancer Center in theirs. Both institutions, the Indiana University Melvin and Bren Simon Cancer Center ...
Leggi tutto

USPSTF Recommendation on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer

Aug 22, 2019 - As reported in JAMA, the U.S. Preventive Services Task Force (USPSTF) recommended risk assessment and, if indicated, genetic counseling and testing for potentially harmful BRCA1/2 mutations in women with a personal or family history of breast, ovarian, tubal, ...
Leggi tutto

FDA Approves Pembrolizumab for PD-L1+ Esophageal Cancer

July 31, 2019 - The FDA has approved pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (combined positive score ≥10) as determined by an FDA-approved test, ...
Leggi tutto

FDA Grants Bempegaldesleukin Plus Nivolumab Breakthrough Designation in Melanoma

Aug 1, 2019 - The FDA granted a breakthrough therapy designation to the combination of bempegaldesleukin (NKTR-214) and nivolumab for the treatment of patients with previously untreated unresectable or metastatic melanoma. The designation is based on results from a cohort ...
Leggi tutto

FDA approves first therapy for rare joint tumor

Aug 2, 2019 - Today, the U.S. Food and Drug Administration granted approval to pexidartinib capsules for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not responsive to ...
Leggi tutto

FDA Grants Priority Review to Avapritinib for GIST

Aug 7, 2019 - The FDA has granted a priority review designation to a new drug application (NDA) for avapritinib for the treatment of adult patients with PDGFRA exon 18–mutant gastrointestinal stromal tumors (GIST), regardless of prior therapy, as well as for patients ...
Leggi tutto

FDA Grants Acalabrutinib Breakthrough Designation for CLL

Aug 14, 2019 - The FDA has granted a breakthrough therapy designation to acalabrutinib for the treatment of patients with chronic lymphocytic leukemia (CLL). The designation is based on findings from the interim analyses of the phase III ELEVATE-TN and ASCEND (ACE-CL-309) ...
Leggi tutto

FDA approves third oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor

Aug 15, 2019 - The U.S. Food and Drug Administration today granted accelerated approval to entrectinib, a treatment for adult and adolescent patients whose cancers have the specific genetic defect, NTRK (neurotrophic tyrosine receptor kinase) gene fusion and for whom there ...
Leggi tutto

FDA Review Finds No Increased Risk of Prostate Cancer With Parkinson’s Disease Treatments Containing Entacapone

Aug 15, 2019 - A U.S. Food and Drug Administration (FDA) review of additional data found no increased risk of prostate cancer with the use of entacapone to treat Parkinson’s disease. The FDA conducted this review after an earlier trial - the Stalevo Reduction in Dyskinesia ...
Leggi tutto

FDA Approves Fedratinib for Myelofibrosis

Aug 16, 2019 - The FDA has approved fedratinib for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis. The approval is based on findings from the phase III JAKARTA2 ...
Leggi tutto